Orion published Interim Report for January-September 2019 on Wednesday 23 October 2019.
Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.
8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.
The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
|11/28/2019||Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%|
|11/28/2019||192,172 Orion Corporation A shares converted into B shares|
|11/4/2019||125,000 Orion Corporation A shares converted into B shares|
|10/28/2019||Composition of the Nomination Committee of Orion Corporation|
|12/9/2019||Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND|
|12/2/2019||Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND|
|11/4/2019||Orion Research Foundation grants 902 000 euros for research in 2020|
|10/7/2019||Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.